RxDoctor Payments Data

Anayancy Driscoll Luna

Family · Mission, TXNPI 1831591064

Payments from drug & device makers

$1,877in general payments, 2019–2025

Across 65 payments — averaging $28.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$553
  • Lilly USA, LLC$550
  • AstraZeneca$324
  • Amgen$265
  • Bayer$48
  • Phadia US Inc.$46
  • plus $91 from 4 others

What the payments were for

  • Food & beverage$1,877100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk17$553
Lilly USA, LLC15$550
AstraZeneca14$324
Amgen10$265
Bayer2$48
Phadia US Inc.2$46
Pfizer2$32
AbbVie1$24
Astellas Pharma US Inc1$20
Abbott1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,877 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$14,403
Medicare patients
15
Services billed
300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$61,698
SynjardyEmpagliflozin/Metformin Hcl23$32,887
MounjaroTirzepatide30$31,847
MyrbetriqMirabegron12$12,691
LinzessLinaclotide12$12,632
PaxlovidNirmatrelvir/Ritonavir11$1,359
Rosuvastatin Calcium43$598
Famotidine40$592
Tamsulosin Hcl34$475
Atorvastatin Calcium46$463
Olmesartan Medoxomil21$385
Levothyroxine Sodium38$353
Buspirone Hcl18$341
Gabapentin31$273
Omeprazole20$262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$553$61,69859 claims
Lilly USA, LLCMounjaro$550$31,84730 claims
Astellas Pharma US IncMyrbetriq$20$12,69112 claims
AbbVieLinzess$24$12,63212 claims
PfizerPaxlovid$32$1,35911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.

Other family in Mission

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →